HC Wainwright Reiterates "Buy" Rating for Mineralys Therapeutics (NASDAQ:MLYS)

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report)'s stock had its "buy" rating reaffirmed by analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They presently have a $42.00 price target on the stock. HC Wainwright's price target would indicate a potential upside of 173.62% from the company's previous close. HC Wainwright also issued estimates for Mineralys Therapeutics' Q2 2025 earnings at ($0.85) EPS, Q3 2025 earnings at ($0.92) EPS, Q4 2025 earnings at ($1.00) EPS, FY2025 earnings at ($3.59) EPS, FY2026 earnings at ($3.22) EPS, FY2027 earnings at ($3.50) EPS, FY2028 earnings at ($1.75) EPS and FY2029 earnings at $1.28 EPS.

Several other equities research analysts have also weighed in on MLYS. Guggenheim reiterated a "buy" rating on shares of Mineralys Therapeutics in a research note on Monday, February 24th. The Goldman Sachs Group lowered their target price on Mineralys Therapeutics from $28.00 to $24.00 and set a "buy" rating for the company in a report on Thursday, February 13th.

Mineralys Therapeutics Price Performance

Shares of MLYS stock traded down $0.01 on Tuesday, hitting $15.35. 779,188 shares of the stock traded hands, compared to its average volume of 469,430. The company's fifty day moving average is $14.29 and its 200 day moving average is $12.47. Mineralys Therapeutics has a 1-year low of $8.24 and a 1-year high of $18.38. The company has a market capitalization of $1.00 billion, a PE ratio of -4.22 and a beta of -0.30.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($0.79) earnings per share for the quarter, beating the consensus estimate of ($1.02) by $0.23. As a group, equities research analysts expect that Mineralys Therapeutics will post -4.23 EPS for the current year.

Insider Buying and Selling at Mineralys Therapeutics

In other news, CEO Jon Congleton sold 15,319 shares of the business's stock in a transaction that occurred on Friday, April 11th. The stock was sold at an average price of $12.19, for a total transaction of $186,738.61. Following the completion of the transaction, the chief executive officer now directly owns 862,289 shares in the company, valued at approximately $10,511,302.91. The trade was a 1.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider David Malcom Rodman sold 11,366 shares of the firm's stock in a transaction that occurred on Wednesday, May 14th. The shares were sold at an average price of $15.29, for a total value of $173,786.14. Following the completion of the sale, the insider now owns 106,669 shares in the company, valued at approximately $1,630,969.01. This represents a 9.63% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 104,579 shares of company stock worth $1,534,353. 25.56% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in MLYS. Jennison Associates LLC increased its holdings in shares of Mineralys Therapeutics by 55.4% during the fourth quarter. Jennison Associates LLC now owns 1,082,006 shares of the company's stock valued at $13,319,000 after purchasing an additional 385,726 shares during the period. Barclays PLC grew its position in Mineralys Therapeutics by 281.8% in the 3rd quarter. Barclays PLC now owns 38,218 shares of the company's stock valued at $463,000 after buying an additional 28,208 shares in the last quarter. Wellington Management Group LLP increased its stake in Mineralys Therapeutics by 43.0% during the 4th quarter. Wellington Management Group LLP now owns 91,529 shares of the company's stock valued at $1,127,000 after buying an additional 27,531 shares during the period. Proficio Capital Partners LLC bought a new stake in shares of Mineralys Therapeutics during the 4th quarter worth about $285,000. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of Mineralys Therapeutics by 0.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 214,906 shares of the company's stock worth $2,645,000 after acquiring an additional 1,307 shares during the period. Institutional investors and hedge funds own 84.46% of the company's stock.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.